Shares of Chinese biopharma companies rise in Hong Kong — CNBC
Shares of Chinese biopharmaceutical companies rose in Hong Kong on Monday after reports that the United States is considering rules that could allow U.S. pharmaceutical companies to continue entering into most licensing deals with Chinese drug developers. This was reported by CNBC.
Shares of Innovent Biologics rose 6%, Akeso climbed 8%, and CSPC Pharmaceutical Group gained more than 6%. HUTCHMED shares added 3%, while Sino Biopharmaceutical rose 8%. The Hang Seng Biotech Index increased by more than 5%.
Draft U.S. Treasury rules
According to Reuters, the U.S. Treasury Department is preparing rules that are likely to allow U.S. pharmaceutical companies to invest in promising drugs being developed by Chinese firms. An exception may apply to developments involving pathogens or biotechnologies that could be used as weapons.
More current news is available on the UA.News Telegram channel Telegram.
The rules have not yet been approved and may change, Reuters notes. Such an approach would distinguish the biopharmaceutical sector from the artificial intelligence and semiconductor industries, for which the United States has tightened restrictions on China.
Licensing deals
According to GlobalData data cited by Reuters, in 2025 Chinese firms accounted for nearly half of U.S. drug licensing deals with foreign companies. In May, Pfizer announced a partnership with Innovent worth up to $10.5 billion, covering the research and development of 12 oncology programs.
According to NMPA data cited by Nomura, a record 81 licensing deals with a total value of $110 billion were concluded in the first half of 2026. Nomura believes that investors are now largely overlooking recurring geopolitical concerns regarding the sector, given the value of Chinese companies in developing new medicines.
